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Abstract: Artemisia capillaris Thunb. (A. capillaris, Yin-Chen in Chinese) is a traditional medicinal 
herb with a wide spectrum of pharmacological properties ranging from effects against liver dys-
function to treatments of severe cirrhosis and cancer. We used relevant keywords to search elec-
tronic databases, including PubMed, Medline, and Google Scholar, for scientific contributions re-
lated to this medicinal herb and the pharmacokinetics of its components. The pharmaceutical effects 
of A. capillaris contribute to the treatment not only of viral hepatitis, cirrhosis, and hepatocellular 
hepatoma, but also metabolic syndrome, psoriasis, and enterovirus in the clinic. The bioactive com-
pounds, including scoparone, capillarisin, scopoletin, and chlorogenic acid, exhibit antioxidant, 
anti-inflammatory, antisteatotic, antiviral, and antitumor properties, reflecting the pharmacological 
effects of A. capillaris. The pharmacokinetics of the main bioactive compounds in A. capillaris can 
achieve a maximum concentration within 1 hour, but only chlorogenic acid has a relatively long 
half-life. Regarding the use of the A. capillaris herb by health professionals to treat various diseases, 
the dosing schedule of this herb should be carefully considered to maximize therapeutic outcomes 
while lessening possible side effects. 
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1. Introduction 
The original uses of Artemisia capillaris Thunb. (A. capillaris, Yin-Chen in Chinese) in 
traditional Chinese medicine included the treatment of pyrexia, jaundice, and dysuria. 
Current basic studies of traditional Chinese medicine aim to find molecular, cytological 
and pharmacological evidence supporting the use of traditional Chinese herbal medicines 
to confirm the nature of active ingredients and to explore the roles of these compounds in 
the treatment of various diseases. Studies of this traditional herb provide reliable empiri-
cal evidence for the development and progress of this traditional Chinese medicine, which 
has been widely used in the treatment of various diseases ranging from liver inflamma-
tion to severe cirrhosis and liver cancer [1–3]. Previous studies have shown that the whole 
plant exerts antioxidant, anti-inflammatory, antisteatotic, antiviral, and antitumor effects 
[4–7]. Most of the therapeutic effects can be attributed to the major or minor compounds 
found in medicinal herbs [8]. 
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However, the bioactive components of an herb are influenced by the plant species 
and origin. For example, the clinical use of Artemisia in traditional Chinese medicine in-
cludes A. capillaris and Artemisia scoparia (A. scoparia) [9]. Though A. capillaris is the main 
species used in medicinal formulations, A. scoparia contains higher levels of the essential 
active compound scoparone, whereas chlorogenic acid is abundant in A. capillaris [9]. The 
harvested time and region of the plant also affect the chemical compositions of bioactive 
compounds. Both capillarisin and scoparone (6,7-dimethylesculetin) content reach peak 
levels in the leaf of A. capillaris at the end of July. However, the maximal level of capillar-
isin and scoparone is detected in the capitulum in early August and early September, re-
spectively [10]. The appropriate time to harvest A. capillaris is an important consideration 
that affects pharmacological actions, including possible toxicity from scoparone. Thus, the 
therapeutic benefits of A. capillaris are influenced by various parts of the plant and harvest 
time, and should be balanced based on the contents of bioactive components. 
The level of bioactive compounds determines an individual’s pharmacokinetic and 
pharmacodynamic reactions to herbal medicines. Recent studies have invested consider-
able efforts into exploring the multicomponent pharmacokinetics of herbal medicines and 
to elucidate relevant metabolic processes. For instance, an herbal formula containing A. 
capillaris was found to be disproportional to its administering dose in the area under the 
curve (AUC) by monitoring its bioactive components [11], which indicated pharmacoki-
netic saturation leading to excessive dosage or potential interaction with other drugs. The 
pharmacokinetic investigation of A. capillaris combined herbal formula upon dose ap-
peared to interact with spironolactone, including the urinary sodium-to-potassium ratio 
[12]. In addition, a lack of information on the therapeutic window and pharmacodynamics 
that guide pharmacokinetics makes the efficacy and safety of herbal medicine questiona-
ble. 
Previous studies reported pharmacokinetic properties or pharmacological activity of 
A. capillaris aims on one bioactive component or single therapeutic function. Few reviews 
summarize the pharmacokinetic properties of major bioactive compounds as well as cur-
rently proved pharmacological usage as suggestions for future potential applications of 
the plant. To the best of our knowledge, A. capillaris has been known for the treatment of 
liver disease but awareness is rare for the treatment for metabolic syndrome, psoriasis, or 
antifibrotic effects that indicate that this plant has an expanded range of therapeutic ac-
tivities. Thus, the present review of pharmacological effects of A. capillaris and linking to 
the pharmacokinetics of extracted bioactive compounds aims to discover additional ap-
plications of this herbal medicine. 
2. Research Methods 
Scientific search engines, such as PubMed, Medline, and Google Scholar were used 
to collect all published articles on ethnomedicinal use, biological properties, and pharma-
cokinetics of A. capillaris. A synopsis of this search is presented in this review. Acquired 
manuscripts were assessed and identified based on the title and abstract. The following 
search terms were used as keywords: Artemisia, Artemisia capillaris, Yin-Chen (Chinese 
name), Yin-Chen-Hao-Tang (an ancient Chinese formula), and pharmacokinetics. The ref-
erence lists of retrieved publications were also examined to identify other relevant studies. 
3. Pharmacological Effects of Artemisia capillaris 
3.1. Viral Hepatitis B Infection 
Hepatitis B virus (HBV) infection can progress to liver cirrhosis or liver cancer. At 
present, the therapeutic options for this disease are limited by agents used for eradication 
of HBV or of side effects of antiviral therapies. Compounds isolated from A. capillaris in-
hibit the secretion of HBsAg or HBeAg or replication of HBV DNA [13]. HBeAg secretion 
and HBV DNA replication in HepG cells are significantly inhibited by 90% ethanol extract 
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of A. capillaris [14], and this activity is due to chlorogenic acid analogs and enynes found 
in A. capillaris [15]. 
3.2. Cirrhosis and Hepatoprotective Effects 
Cirrhosis refers to the late stage of scarring caused by repeated pathological destruc-
tion and regeneration of the liver due to various forms of liver diseases. A strategy for the 
prevention of liver damage involves pretreatment with an aqueous extract of A. capillaris, 
which significantly reduces oxidative stress in the liver induced by 2,2′-azobis(2-amidi-
nopropane) dihydrochloride (AAPH), as demonstrated by a decrease in the level of liver 
injury based on the enzyme markers aspartate transaminase (AST) and alanine transami-
nase (ALT) in rats [16]. Herbal formulations consisting of A. capillaris and Alisma canalicu-
latum (Saeng-kankunbi-tang, SKT) also prevent tert-butyl hydroperoxide (tBHP)-induced 
oxidative injury in HepG2 hepatocytes and acute oxidative hepatic damage caused by 
carbon tetrachloride (CCl4) in mice [17]. 
Antifibrotic effects of A. capillaris have also been reported. The β-sitosterol compo-
nent derived from A. capillaris alleviates dimethylnitrosamine (DMN)-induced hepatofi-
brosis in mice [18]. In a model of bile duct ligation (BDL)-induced cholestatic fibrosis, 
aqueous extract of A. capillaris suppresses the expression of fibrogenic factors, including 
alpha-smooth muscle actin (α-SMA), platelet-derived growth factor (PDGF), and trans-
forming growth factor-beta (TGF-β), and significantly reduces the levels of cholestatic 
markers malondialdehyde (MDA) in the serum and hydroxyproline in the liver after 2 
weeks of treatment in rats [19]. An increase in the AST, ALT, and MDA levels induced by 
30% alcohol plus pyrazole is also ameliorated by aqueous extract of A. capillaris in a rat 
model [20]. This hepatoprotective effect is attributed to an enhancement of antioxidant 
activity, including glutathione peroxidase (GSH-Px), glutathione reductase (GSH-Rd), 
catalase, and superoxide dismutase (SOD) [20]. However, another study demonstrated 
that 5-week treatment with aqueous A. capillaris extract did not alter liver enzymes, in-
cluding ALT, AST, and alkaline phosphatase (ALP), in a rat model of CCl4-induced he-
patic fibrosis, although different results were obtained in the case of Artemisia iwayomogi 
[21]. Another study reached a similar conclusion after administration of methanol extract 
of A. capillaris in rats with bile duct ligation; the results indicated that the serum levels of 
AST, ALT, and ALP and hepatic levels of hydroxyproline were significantly reduced in 
the Polygonum aviculare-treated group but not in the groups treated with A. capillaris and 
aqueous biphenyl dimethyl dicarboxylate [22]. Variability of hepatoprotective effects may 
be due to extraction or cultivation and should be confirmed by assessment of biological 
components. 
3.3. Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) requires effective treatment due to low 10% 5-year 
survival rate of this disease [23]. Increasing evidence indicates that A. capillaris can effi-
ciently suppress the proliferation of human hepatoma cells, and ethanol extract of A. capil-
laris exhibits dose-dependent antiproliferative effects against Huh7 and HepG2 human 
hepatoma cells mediated by inhibition of cancer cell migration via interleukin-6 (IL-6)-
dependent regulation of the signal transducer and activator of transcription 3 (STAT3) 
pathway [24]. In HepG2 human hepatocarcinoma cells, aqueous extract of A. capillaris in-
hibits nuclear translocation of NF-κB and blocks the degradation of I-κB alpha, leading to 
inhibition of inflammatory proteins, such as inducible nitric oxide synthase (iNOS), cy-
clooxygenase-2 (COX-2), and tumor necrosis factor (TNF)-alpha [25]. Additionally, water-
soluble macromolecular components of A. capillaris dose-dependently inhibit the prolifer-
ation of human hepatoma SMMC-7721 cells by inducing the cell-cycle arrest at the G0/G1 
phase [26]. Ethyl acetate extract of A. capillaris can effectively inhibit the growth and in-
duce apoptosis of hepatocellular carcinoma cells, and these effects are presumed to be 
mediated by inhibition of angiogenesis via the blockade of the PI3K/AKT/mTOR signaling 
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pathway [27]. Dried leaves of A. capillaris use a similar mechanism to induce apoptosis in 
HepG2 and Huh7 cells and to suppress tumor growth in mouse xenograft models [28]. 
3.4. Metabolic Syndrome and Diabetes 
Metabolic syndrome is associated with a fivefold higher risk for type 2 diabetes 
(T2DM). Overabundance of circulating fatty acids is the major contributor to pathophysi-
ology of metabolic syndrome. Fatty acids inhibit antilipolytic effect of insulin and induce 
lipolysis of stored triacylglycerol molecules in the adipose tissue, which leads to insulin 
resistance [29]. Glucosidase inhibitors delay the absorption of carbohydrates to decrease 
postprandial hyperglycemia. The inhibitory effect of A. capillaris on α-glucosidase is the 
most potent among that of 12 various Artemisia species, and this effect is even stronger 
than inhibition by acarbose [30]. Rats administered a high-fat diet (HFD) were treated 
with A. capillaris extracts for 7 weeks, and the body weight and levels of serum triglycer-
ides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-c) of 
treated rats were measured and found to be lower than those in the HFD-induced obesity 
control group; however, the levels of high-density lipoprotein cholesterol (HDL-c) were 
not significantly different between the groups [31]. Similar results were obtained in an-
other study using a traditional A. capillaris formula. The treatment abrogated an increase 
in liver enzymes and lipid parameters, such as TG, TC, and LDL-c, but not HDL-c, in HFD-
fed rats. These effects were apparently mediated by miR-122-induced downregulation of 
fatty acid synthase genes in HepG2 cells [32]. 
Free fatty acids induce insulin resistance and inflammation in insulin-targeted or-
gans, indicating a major link between obesity, insulin resistance, inflammation, and T2DM 
development [33]. Free fatty acid-induced steatosis was relieved and nonalcoholic steato-
hepatitis (NASH)-related mechanisms were inhibited in HepG2 cells treated with 30% 
ethanolic extract of A. capillaris, including activation of c-Jun NH2 terminal kinase (JNK) 
and p53-upregulated modulator of apoptosis (PUMA) [34]. An n-BuOH fraction of meth-
anol extract of A. capillaris contains vicenin 2, which potently inhibits diabetes-targeting 
enzymes α-glucosidase, protein tyrosine phosphatase 1B (PTP1B), and rat lens aldose re-
ductase (RLAR) [35]. However, A. capillaris extract combined with Alisma rhizome extract 
does not alter the levels of lipid metabolites, such as triacylglycerol and diacylglycerol, in 
diabetic mice [36]. In contrast, Hericium erinaceus cultivated with A. capillaris can elevate 
the HDL level and lower atherogenic index and cardiac risk factor values in hyper-
lipidemic rats; these effects were more pronounced than the effects of currently used 
drugs simvastatin and atorvastatin [37]. Thus, the regulatory effects of A. capillaris on 
dyslipidemia appear to be influenced by additions of other herbs. 
3.5. Dermatitis, Psoriasis, and Skin Carcinogenesis 
Atopic dermatitis is an inflammatory skin disease caused by an imbalance of Th cells, 
the overexpression of COX-2 and iNOS, which generate nitric oxide (NO) and prostaglan-
din E2, respectively, and stimulation of macrophages by lipopolysaccharide. Topical ap-
plication of A. capillaris for 4 weeks reduced the atopic dermatitis scores and plasma levels 
of histamine and IgE in Dermatophagoides farinae-sensitized Nc/Nga mice [38]. Solid fer-
mentation of Ganoderma lucidum on A. capillaris leaves reduced the expression of endothe-
lial nitric oxide synthase (eNOS) in mice with 2,4-dinitrofluorobenzene (DNFB)-induced 
atopic dermatitis [39]. A. capillaris extract cream has been locally applied to skin lesions in 
a mouse model of imiquimod (IMQ)-induced psoriasis-like disease, and the level of intra-
cellular adhesion molecule-1 (ICAM-1), modified psoriasis area, and severity index (PASI) 
scores of treated mice were significantly lower than those of mice in other experimental 
groups [40]. Moreover, the chloroform fraction of methanolic extract of A. capillaris mark-
edly decreased the number and incidence of tumors in mice with 12-dimethylbenz(a)an-
thracene (DMBA)-induced epidermal carcinogenesis compared with the results obtained 
using other anticarcinogenic medicinal herbs, including Taxus cuspidata, Anthriscus syl-
vestris, and Curcuma longa [41]. 
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3.6. Enterovirus 71 (EV71) and Helicobacter pylori (H. pylori) 
Infectious diseases have affected humans for centuries and have civilization-altering 
consequences. Studies in human foreskin fibroblasts and rhabdomyosarcoma cells 
demonstrated that aqueous extract of A. capillaris dose-dependently protects against EV71 
infection, mainly due to inhibition of viral internalization [42]. Acidic polysaccharides 
from A. capillaris are potent inhibitors of adhesion of H. pylori to erythrocytes; however, 
this effect was less potent than that of acidic polysaccharides from Panax ginseng (P. gin-
seng) [43]. Aqueous extract of A. capillaris has no acid-neutralizing activity and does not 
prevent histamine secretion from HMC-1 mast cells; however, pretreatment with this 
aqueous extract decreases HCl/ethanol-induced gastric mucosal lesions [44,45]. A sum-
mary of the therapeutic effects of A. capillaris is provided in Table 1. 
Table 1. Experimental therapeutic effects of Artemisia capillaris. 
Disease Extract Doses/Concentrations Time  
Period 






ethanol 76.1 μg/mL NR 
inhibition of HBeAg secretion and 
HBV DNA replication in HepG cells chlorogenic acid [14] 
Cirrhosis 
water 10 mg/kg NR alleviation of hepatic fibrosis in a 
DMN-induced mouse model 
β-sitosterol [18] 
water 25 or 50 mg/kg 2 weeks 
suppression of fibrogenic factors, in-
cluding hepatic α-SMA, PDGF, and 
TGF-β 
NR [19] 
water 7.5 g/kg 7 days lowering of AST and ALT in a rat 
model of AAPH liver damage 
NR [16] 
water 50 or 100 mg/kg 10 days 
amelioration of AST, ALT, and MDA 
in an alcohol-pyrazole-fed rat model; 
an increase in antioxidant activity due 
to GSH-Px, GSH-Rd, catalase, and 
SOD 
NR [20] 
water 25 or 50 mg/kg 6 weeks 
unchanged ALT, AST, and ALP in a 









100 and 250 μg/mL NR 
inhibition of IL-6 mediated STAT3 
pathway in Huh7 and HepG2 human 
hepatoma cells 
NR [24] 
water 50, 150, and 300 mg/kg NR 
Inhibition of NF-kappaB transloca-
tion, inhibition of iNOS, COX-2, and 
TNF-alpha in HepG2 cells 
NR [25] 





50 and 100 μg/ml NR 
Induction of apoptosis of HCC cells 




ethanol 100 μg/mL 15 days 
induction of apoptosis in HepG2 and 
Huh7 cell; suppression of tumor 







nol 0.4% and 0.8% extract 7 weeks 
lowering of TG, TC, and LDL-c levels 
in high-fat diet-fed rats; a decrease in 
fatty acid synthase expression via 
miR-122 
NR [31,32] 






100 μg/mL NR inhibition of activation of JNK and 




IC50 values: 270.5 μM 
(α-glucosidase); 7.85 
μM (RLAR); 139.75μM 
(PLAR) 
NR 
inhibition of α-glucosidase, PTP1B, 
and RLAR. 








ethanol 10 mg 4 weeks 
reduction in atopic dermatitis scores, 
histamine, and IgE in Dermatopha-










ethanol 250 mg/kg 5 days 
lowering of ICAM-1 and modified 
PASI scores in a mouse model of in-












50 g sample in 500 mL 
of MeOH 7 days 
reduction in the tumor number and 
incidence in a mouse mode of DMBA-









water 10 μg/mL NR effect against EV71 infection due to inhibition of viral internalization chlorogenic acid [42] 
water 0.2–2.8 mg/mL NR 




water 200 or 400 mg/kg NR 
inhibition of lipid peroxide formation 
due to SOD activation, a reduction in 
proinflammatory cytokines IL-6 and 
IL-1β mediated by NF-κB downregu-
lation 
NR [44] 
 ethanol 30 or 100 mg/kg 1 hr prior 
attenuation of ethanol-induced proin-
flammatory cytokines IL-1β and inter-
feron-γ and ICAM-1 
NR [45] 
α-SMA, alpha-smooth muscle actin; AAPH, 2,2′-azobis(2-amidinopropane) dihydrochloride; ALT, alanine transaminase; 
ALP, alkaline phosphatase; AST, aspartate transaminase; CCl4, carbon tetrachloride; COX-2, cyclooxygenase-2; GSH-Px, 
glutathione peroxidase; GSH-Rd, glutathione reductase; ICAM-1, intracellular adhesion molecule-1; IL-1β, interleukin-1 
beta; IL-6, interleukin-6; iNOS, inducible nitric oxide synthase; LDL-c, low-density lipoprotein cholesterol; JNK, c-Jun 
NH2-terminal kinase; MDA, malondialdehyde; NASH, nonalcoholic steatohepatitis; NF-κB, nuclear factor kappa B; NR, 
not reported; PASI, psoriasis area and severity index; PDGF, platelet-derived growth factor; PTP1B, protein tyrosine phos-
phatase 1B; PUMA, p53-upregulated modulator of apoptosis; RLAR, rat lens aldose reductase; SOD, superoxide dis-
mutase; STAT3, signal transducer and activator of transcription 3; TC, total cholesterol; TG, triglycerides; TGF-β, trans-
forming growth factor beta; TNF-alpha, tumor necrosis factor alpha. 
4. Pharmacokinetics of Bioactive Compounds Found in Artemisia capillaris 
A. capillaris have been intensively studied to evaluate its effects on healthcare, 
demonstrating that A. capillaris has protective effects against hepatitis, cirrhosis, cancer, 
metabolic syndrome, dermatitis, and microbes, which triggered additional scientific in-
quiries. Numerous bioactive compounds were therefore extracted and found to have ben-
eficial effects, including anti-inflammatory, antioxidant, antitumor, or even anti-HIV ac-
tivities. The most commonly identified constituents include scoparone, capillarisin, and 
chlorogenic acid (Table 2) [46–49]. Their chemical structures are shown in Figure 1. From 
a practical perspective, these bioactive compounds composed of the pharmacology of A. 
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capillaris need rigorous pharmacokinetics research to provide science-based dosage rec-
ommendations for various therapeutic properties of A. capillaris. Realizing the pharmaco-
kinetics of bioactive compounds in A. capillaris could improve the administration schedule 
to achieve medicinal effects in an efficient manner. The pharmacokinetics of bioactive 
compounds in A. capillaris are discussed below. 
Table 2. Bioactive compounds of Artemisia capillaris extraction studies. 





Detection Ions References 
[M − H]- [M + H] + 
Scoparone 1 supercritical car-
bon dioxide with 
ethyl acetate 
206.20  207 [46–49] Capillarisin 1 316.27 315 (M−) 317 (M+) 
Chlorogenic acid 2 354.31 191 163 [46,47,49] 
Scopoletin 2 
ethyl acetate and 
water 
192.17 104 234 3 [47–49] 
Capillin 168.20  140 3 
[48,49] 
Isoscopoletin 192.17 176 4 133 
Capillene 154.21  153 3 
Capillartemisin B 316.40   
Cirsimaritin 314.29  315 
Capillarisin-7-methyl 
ether 330.34   
[48] artepillin A 316.40   
Artepillin C 300.40   






164.20  165 
[47] 
Caffeic acid 180.16 135 163 
Phenol 94.11  95 
o-cresol 108.14  108 (M+) 
m-cresol 108.14  109 (M+) 
p-cresol 108.14  93.0 
(M+) 
2-ethylphenol 122.17  107 3 
4-ethylphenol 122.17  107 3 
Artemisidin A 
methanol 
642.50   
[49] 
Artemicapins A 250.20   
Artemicapins B 236.18   
Artemicapins C 206.15   
Artemicapins D 440.4   
other 70 known com-
pounds    
1 Compounds were found in all references. 2 Compounds were found in three references. 3 Ions 
were detected by GC-MS. 4 Ions were detected by MS–MS. 
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Figure 1. The chemical structure of commonly identified constituents in Artemisia capillaris. 
4.1. Scoparone 
Scoparone is considered the main and most important active constituent of A. capil-
laris. Analysis of Soxhlet extracts of A. capillaris indicated that the plant contains higher 
levels of scoparone than the levels of capillarisin or chlorogenic acid [46]. This compound 
was considered of interest due to its preventive and therapeutic effects against liver dis-
ease, which prompted subsequent investigations [50,51]. Scoparone isolated from A. capil-
laris has been shown to have antioxidant properties demonstrated by a reduction in the 
MDA and ALT levels in cold-preserved rat hepatocytes [52]. Scoparone decreases the lev-
els of interleukin (IL)-1-beta, IL-6, and TNF-alpha due to anti-inflammatory activities of 
the compound and suppresses the levels of iNOS and COX-2 in IFN-gamma- or LPS-stim-
ulated cells [53]. Moreover, scoparone inhibits the transcriptional activity of peroxisome 
proliferator-activated receptor gamma (PPARγ) and downregulation of the target genes, 
and this effect leads to inhibition of triglyceride (TG) accumulation in mature adipocytes 
[54]. Choleretic effect of scoparone is indirectly potentiated by cytochrome P4501A2 via 
the bile salt export pump promoter [55]. Scoparone is considered a potential hepatopro-
tective candidate for hepatitis therapy based on published evidence [56]. Additionally, 
scoparone 60 mg/kg daily could alleviate angiotensin II infusion-induced cardiac hyper-
trophy and fibrosis in mice with maintaining cardiac output, left ventricular pressure, and 
left ventricular workload [57,58]. 
Analysis of pharmacokinetic parameters of scoparone could achieve a wide range of 
the Cmax values from 0.02 mg/L or up to 16.1 mg/L accompanying with standard com-
pounds as Yin-Chen-Hao-Tang ingredients, and most Tmax values ranged from 6 to 54 min 
with the exception of one study that reported a Tmax value of 1.9 h after combined admin-
istration with Gardenia jasminoides Ellis [59]; the corresponding elimination half-life ranges 
from 25.8 min to 5.11 h [11,59–63]. The IC50 value for scoparone-associated significant in-
hibition of the proliferation of DU145 prostate cancer cells is 8.5 mg/L (41.3 μmol/L) [64]. 
High levels of scoparone in A. capillaris are apparently responsible for inhibition of pros-
tate cancer proliferation. Consequently, two characteristics of scoparone have been no-
ticed. First, a combination of geniposide delay absorption of scoparone and combined 
with geniposide and rhein increased the AUC [63]. Additionally, the herbal formula Yin-
Chen-Hao-Tang has been used to illustrate nonlinear pharmacokinetic properties of sco-
parone, which represents a potential enhancement of pharmacological effects of this drug 
[11]. 
4.2. Scopoletin 
Scopoletin isolated from A. capillaris contributes to bile secretion similarly to scopa-
rone but has no effect on bile acid and cholesterol secretion [48]. These effects may be due 
to inhibition of lipid biosynthesis, which results in downregulation of gene expression 
related to cholesterol, triglyceride synthesis, and inflammation induced by steatosis [65]. 
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This compound may assist in lowering postprandial hyperglycemia and improving anti-
diabetic treatments [66]. Scopoletin can enhance histone deacetylase expression to inactive 
p53 in human lung fibroblasts, which leads to autophagy-related antiaging effects [67]. 
Moreover, scopoletin is cytotoxic toward cancer cells, such as prostate cancer cells (PC-3) 
and acute lymphoblastic leukemia cells [68,69]. Although NF-κB activation by scopoletin 
implies a resistance mechanism of cancer cells, the main resistance mechanisms, such as 
ATP-binding cassette (ABC) transporters, EGFR, and TP53, do not affect cellular re-
sistance to scopoletin [70]. 
Oral administration of pure scopoletin at the doses of 5, 10, or 20 mg/kg results in the 
Cmax values in the plasma of 49.8, 101.3, or 217.3 μg/L, respectively, reached within 0.4 h 
[71]. Another study of oral administration at a dose of 50 mg/kg resulted in the Cmax value 
of 0.4 μg/L within 14 min. However, treatment with a decoction prepared from 720 g of 
A. capillaris resulted in a relatively low plasma concentration of only 3.5 μg/L after feeding 
[61]. Similarly, administration of Radix angelicae pubescentis extract containing 0.055 mg/kg 
scopoletin did not result in detectable levels of the compound in rat plasma [72]. It has 
also been revealed with a short elimination half-life in dogs [73]; thus, scopoletin is not 
easily absorbed or rapidly metabolized when administered in an herbal formula. The IC50 
value of scopoletin for human CCRF-CEM leukemia cells is 499.6 μg/L [69]. These findings 
indicate that the level of scopoletin in A. capillaris and Radix angelicae pubescentis is insuf-
ficient to detect pharmacological effects of pure scopoletin against leukemia cells in the 
clinic. 
4.3. Capillarisin 
Capillarisin is derived naturally from chromone. The compound has antioxidant, 
anti-inflammatory, and potential antitumor properties [74], and antioxidant and anti-in-
flammatory activities are regulated via the Nrf2/ARE-dependent pathway and activation 
of ERK, JNK, NF-κB, and MAPK [75–77]. Capillarisin also has inhibitory effects on pros-
tate carcinoma cells, apparently mediated by suppression of the activation of androgen 
receptor, survivin, matrix metalloproteinase (MMP)-2, MMP-9, and STAT3 [78,79]. 
Treatment with Yin-Chen-Hao-Tang (YCHT) formula, which combines 18 g of A. 
capillaris with Gardenia jasminoides Ellis (9 or 12 g) and Rheum palmatum L. (6 g), reported 
two remarkable maximal concentrations of capillarisin of 196 μg/L or 490 μg/L [80,81]. 
The Tmax value for capillarisin administered as a component of the YCHT decoction ranges 
from 5 to 39 min, and the AUC is highly variable, with elimination half-lives ranging from 
26 to 159 min. Capillarisin has notably higher affinity to human serum albumin than that 
of scoparone, indicating that capillarisin bioactivity has a stationary phase [82]. Capillar-
isin (95% (wt)) has inhibitory effects on human hepatoma Hep-G2 and HUH7 cells, with 
the IC50 values of 72 and 105 μg/mL, respectively [46], and the IC50 values for inhibition of 
the migration and proliferation of colon cancer cells are 92.1 and 76.7 μg/mL, respectively 
[83].  
4.4. Capillin 
Capillin extracted from Artemisia capillaris spica inhibits apoptosis induced by trans-
forming growth factor-beta 1 (TGF-β1), which is observed in various inflammatory liver 
diseases [84]. Human leukemia HL-60 cells are induced to undergo apoptosis after treat-
ment with capillin, and this effect is regulated by activation of the JNK pathway [85]. An-
titumor effects of capillin have also been detected in colon carcinoma (HT29 cells), pan-
creatic carcinoma (MIA PaCa-2 cells), epidermoid carcinoma of the larynx (HEP-2 cells), 
and lung carcinoma (A549 cells) [84]. Moreover, capillin is a potent inhibitor of α-gluco-
sidase, protein PTP1B, and RLAR for management of diabetes and related complications 
[86]. However, extraction of capillin from A. capillaris has been rarely reported; thus, the 
pharmacokinetics of capillin are unknown. Further pharmacokinetic studies based on the 
IC50 values should be considered in the investigation of antitumor properties of the com-
pound. 
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4.5. Chlorogenic Acid 
Chlorogenic acid is the most abundant compound (38.5 mg/g) in hydroethanolic ex-
tract of A. capillaris [87]. Chlorogenic acid is also extensively enriched in various foods, 
such as coffee, tea, cocoa, citrus fruits, berry fruits, apples, and pears [88]. The biological 
activities of chlorogenic acid have been reported against various diseases, including met-
abolic syndrome, hypertension, and diabetes [89–91], indicating a broad range of anti-
inflammatory, antihyperglycemic, and antioxidant activities of the compound [92–94]. 
The mechanism of action of chlorogenic acid mainly involves uptake and synthesis of fatty 
acids in the liver by modulating hepatic peroxisome proliferator-activated receptor γ or 
liver X receptors-α (PPARαγ, LXRα) [95]. The compound suppresses inflammation in-
duced by a high-fat diet due to scavenging of reactive oxygen species (ROS) [96]. Chloro-
genic acid regulates apoptosis-related genes, and this effect may contribute to the anti-
cancer effect in a lung cancer cell line [97]. 
Administration of YCHT results in a Cmax for chlorogenic acid of 33 μg/L or 78 μg/L 
within 27 min, but the half-life can be minutes to several days [80,81]. Administration of 
60 mg/kg dose of chlorogenic acid in extracts Lonicerae japonicae Flos achieved a maximum 
concentration of 2.4 mg/L in the plasma of beagle dogs after 1.0 h [98]. Eucommia ulmoides 
extract containing 1.2, 2.6, and 5.1 mg/kg chlorogenic acid acquired Cmax of 22.5, 39.8, and 
61.0 ng/mL, respectively, within 26 min for all three concentrations after its administration 
to rats [99]. Chlorogenic acid has been administered to humans by 10 commercially avail-
able products with an average content of 3.6 mg, which achieved a maximal concentration 
of 0.76 ng/mL after approximately 1 h [100]. Though chlorogenic acid was found to be not 
well-absorbed from the digestive tract [101], the currently available pharmacokinetics of 
chlorogenic acid in A. capillaris revealed rapid time to maximum concentration with up to 
a month of half-life. Future studies in pharmacology of A. capillaris should consider the 
prolonged elimination in the pharmacokinetics of chlorogenic acid. 
4.6. Isochlorogenic Acid 
Other constituents isolated from Artemisia capillaris include isoscopoletin, artepillin, 
esculetin, isochlorogenic acid, β-sitosterol, and quercetin. Natural isochlorogenic acid re-
fers to a mixture of several isomers. Isochlorogenic acid A is the most or second-most 
abundant component found in ethanol extract of A. capillaris [38,87], and is also a major 
bioactive constituent in other medicinal plants such as Lonicerae japonicae Flos, Gynura di-
varicata, and Laggera alata [102–104]. Isochlorogenic acid A probably blocks HBV replica-
tion to provide for potent anti-HBV activity and induces heme oxygenase-1 (HO-1) ex-
pression, which leads to antioxidant effects [104]. The viral load of enterovirus 71 and 
cytokine secretion decreased after treatment with isochlorogenic acid C [105]. Antioxidant 
effects and suppression of profibrogenic factors by isochlorogenic acid B are mediated via 
the Nrf2 and miR-122/HIF-1α signaling pathways to protect against fibrosis in nonalco-
holic steatohepatitis (NASH) [106]. 
The pharmacokinetics of isochlorogenic acid from A. capillaris extracts have not been 
reported. Analysis of pharmacokinetics of isochlorogenic acid after administration of 5.0 
g/kg of Erigeron breviscapus ethanol extract, which contains 16.56 mg/kg isochlorogenic 
acid A and 10.64 mg/kg isochlorogenic acid C, revealed the Cmax values of 1.033 μg/mL 
and 0.230 μg/mL after 1.17 and 0.11 h, respectively [107]. Oral administration of isochloro-
genic acid C at the doses of 5 mg/kg or 25 mg/kg resulted in the Tmax values ranging from 
30 min to 1 h [108]. However, the bioavailability of isochlorogenic acid C is relatively low, 
ranging from 14.4% to 16.9%. Although the compound has a linear pharmacokinetics pro-
file, poor gastrointestinal absorption and low potency of the compound in herbal medi-
cines may diminish potential therapeutic applications of isochlorogenic acid C. 
Analysis of the pharmacodynamic properties of bioactive components of A. capillaris, 
such as the choleretic, anti-inflammatory, and antioxidant effects, are mainly from scopa-
rone, scopoletin, capillarisin, capillin, and chlorogenic acids, while antidiabetic, 
Biomedicines 2021, 9, 1412 11 of 17 
 
antisteatotic, and antitumor effects are from scopolectin, capillarisin, capillin, and chloro-
genic acids (Figure 2). Considering the relatively low plasma concentration detected from 
scopoletin, the antitumor properties of A. capillaris consequently in part come from capil-
larisin, capillin, and chlorogenic acids. Despite the unknown pharmacokinetics of capillin, 
all compounds could reach the corresponding Cmax within an hour and diminished to half-
concentration within 5 hours except for chlorogenic acids, which could last more than a 
month (Figure 3). 
 
Figure 2. Schematic illustration of the bioactive components of Artemisia capillaris contributing to its 
therapeutic effects. Bioactive compounds include scoparone, scopoletin, capillarisin, capillin, 
chlorogenic acid, and isochlorogenic acid, which induce pharmacological effects of A. capillaris in a 
synergistic manner. PC-3: prostate cancer cells; ALL: acute lymphoblastic leukemia cells; LC: lung 
cancer cells; ↓ decrease or inhibit effects; ↑ increase or enhance effects; ↓↑ modulate effects. 
 
Figure 3. The pharmacokinetic extent of bioactive compounds in Artemisia capillaris. The figure il-
lustrates the absorption and elimination of scoparone, scopoletin, capillarisin, and chlorogenic acid 
in vivo after oral administration of Artemisia capillaris extracts. The black symbols represent the max-
imum concentration (Cmax) of the main bioactive compounds, including scoparone, scopoletin, capil-
larisin, and chlorogenic acid. The white symbols represent the half-life (t1/2) of these compounds. A, 
B, C, D indicate the area of the Cmax of scoparone, scopoletin, capillarisin, and chlorogenic acid, re-
spectively. 
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5. Conclusions 
A. capillaris has a wide spectrum of pharmacological properties. In addition to HBeAg 
inhibition, lowering of AST and ALT, and induction of apoptosis of HCC cells, it also 
lowers TG, TC, and LDL, ICAM-1, inhibits α-glucosidase, and causes viral internalization 
and H. pylori adhesion. Published studies have revealed these effects were attributed to 
verified bioactive compounds such as scoparone, scopoletin, capillarisin, capillin, and 
chlorogenic acids. These commonly extracted bioactive compounds induce pharmacolog-
ical effects, including anti-inflammatory, antioxidant, choleretic, antisteatotic, antidia-
betic, and antitumor activities, and synergistically contribute to the therapeutic effects of 
A. capillaris. Considering the pharmacokinetics of main bioactive compounds in A. capil-
laris, the choleretic, anti-inflammatory, and antioxidant effects that partly come from sco-
parone and scopoletin contributing to anti-hepatitis treatment could achieve a therapeutic 
window within a relatively short time. On the other hand, for antisteatotic, antidiabetic, 
and antitumor activities attributed to capillarisin, capillin, and chlorogenic acids with rel-
atively low Cmax and a long half-life, the dosing may need to be adjusted to suit a particular 
therapeutic purpose. Pharmacokinetic parameters of some bioactive compounds in A. 
capillaris, including scoparone and capillarisin, were acquired from the herbal formula 
Yin-Chen-Hao-Tang, which significantly altered the pharmacokinetics of bioactive com-
pounds. Regarding the use of this herb by health professionals for treatments of various 
diseases, the development of A. capillaris in composition or dosing schedule for more ef-
fective and efficient treatment clinically should be considered for future clinical studies in 
patients. 
A worldwide outbreak of respiratory infection beginning in December 2019 has chal-
lenged scientists to find antiviral agents for the treatment of the disease. Researchers pro-
posed the development of Artemisia annua for the treatment of COVID-19 due to its anti-
viral and antioxidant activity in pulmonary fibrosis [109]. A. capillaris belongs to the same 
genus as A. annua, has antioxidant, antiviral, and antifibrotic activities, and contains the 
same bioactive compounds, including scoparone and scopoletin [110,111]. Moreover, A. 
capillaris has been successfully applied in a formula as a complementary treatment for 
patients with pulmonary fibrosis at critical illness and recovery stages in Taiwan [112]. 
The present review describes the pharmaceutical properties and pharmacokinetics of bi-
oactive compounds of A. capillaris. Future studies of A. capillaris, including verifying the 
pharmacokinetics of capillin and isochlorogenic acid, which have antioxidant, antiviral, 
and antitumor effects, alongside considerations of harvest time and different parts of the 
plant, are needed to inform the effective doses of A. capillaris for clinical applications. 
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